痤疮治疗市场 - 全球产业规模、份额、趋势、机会和预测（按治疗分类、配方、类型、痤疮类型、分销管道、地区和竞争格局划分），2021-2031年

全球痤疮治疗市场预计将从2025年的118.7亿美元成长到2031年的166.3亿美元，复合年增长率（CAGR）为5.78%。该市场涵盖多种治疗方法和程序，包括全身性抗生素、外用类视色素和荷尔蒙疗法，旨在调节皮脂分泌、抑制细菌生长和减轻发炎。推动市场成长的关键因素是成人和青少年寻常性痤疮发病率的上升，以及全球对外观和护肤的日益关注。此外，青春痘常常会对患者的自尊心和生活品质产生负面影响，造成沉重的心理负担，促使人们寻求专业的皮肤科治疗，并持续推动对有效治疗方案的需求。

根据美国皮肤病学会的数据，痤疮将在2025年继续成为美国最常见的皮肤病，每年影响多达5,000万美国。如此高的发生率使得稳定的治疗药物供应至关重要。然而，市场面临着与药物治疗长期安全性相关的重大挑战，尤其是显着增加的皮肤不良反应风险和抗生素抗药性。这些安全隐患可能导致患者和医生犹豫不决，限制标准药物疗法的普及，并阻碍整个行业的扩张。

市场驱动因素

消费者对美容和皮肤健康的日益关注是推动市场扩张的主要动力，从根本上改变了皮肤科护理的方式。随着社群媒体和数位平台的普及，人们对皮肤外观的关注度不断提高，患者越来越倾向于选择专业治疗而非暂时性的美容方案，这促使市场对经临床检验、能够弥合化妆品和药品之间差距的产品需求激增。这一趋势正推动着行业主要参与者的快速成长。例如，根据欧莱雅于2024年2月发布的2023年度报告，该公司皮肤科美容部门的销售额年增28.4%，这一增速远超整体美容市场。这凸显了健康意识消费在推动实证痤疮治疗方案广泛应用方面发挥的重要作用。

同时，新型全身和局部药物疗法的推出正在重塑竞争格局，这些疗法解决了传统抗生素相关的安全问题和未满足的医疗需求。製药公司正成功应用创新作用机制，例如雄性激素受体抑制剂，这类药物针对痤疮的荷尔蒙根源，同时最大限度地降低系统性抗药性的风险。近期的数据反映了这些先进治疗方法的快速普及。 Cosmo Pharmaceuticals 在其 2025 年 1 月发布的「2024 财年初步审核业绩」中报告称，Winlevi 已成为美国销量最高的品牌局部痤疮治疗药物，处方笺超过 120 万张。同时，Galderma 在 2024 年 2 月的报告中指出，在治疗性皮肤病学领域强劲成长的推动下，其年度净销售额达到创纪录的 40.82 亿美元。

市场挑战

长期药物治疗带来的安全隐患，尤其是皮肤不良反应和抗生素抗药性风险的增加，对全球痤疮治疗市场构成了重大障碍。随着医学界对长期使用抗生素风险的认识不断加深，处方医师在使用传统高剂量疗法时也变得越来越谨慎。这种临床上的谨慎态度导致处方量减少、疗程缩短，直接限制了现有全身性药物的收入；同时，患者对微生物群紊乱等副作用的担忧进一步降低了用药依从性，并减缓了市场增长。

儘管存在这些担忧，但人们对这些药物的依赖程度仍然很高，凸显了该行业面临的巨大挑战。根据美国疾病管制与预防中心（CDC）的数据显示，到2024年，皮肤科医师开立的口服抗生素处方量将达到约510万个疗程，在所有医学专科中仍将维持最高的处方率。如此高的处方量给皮肤科领域带来了巨大压力，迫使其透过医疗管理计画大幅降低抗生素的使用量，而随着标准治疗通讯协定逐渐减少对这些主要药物的依赖以降低安全风险，市场成长也因此受到限制。

市场趋势

亲水胶体祛痘贴的日益普及正在从根本上改变消费行为，它认可了可见的治疗方法，并为传统的局部用药提供了一种非侵入性的替代方案。与通常隐蔽使用的乳霜不同，这些粘贴式祛痘贴被作为生活方式配件进行销售，既能减少与痘痘相关的社会耻辱感，又能保护皮肤屏障免受接触和外部刺激。这种向便捷一次性包装的转变正在为大型个人护理集团带来显着的商业性成长动力。例如，Church & Dwight 于 2024 年 11 月发布的「2024 财年第三季业绩报告」指出，其国内消费者净销售额的成长主要得益于 HERO 祛痘产品的出色表现，凸显了该品类在其整体产品组合收入中的重要作用。

同时，面向消费者的远距皮肤科服务的扩展正在克服与门诊就诊相关的后勤障碍，使更多人能够获得处方笺级别的治疗。利用非同步咨询，数位健康平台将患者与认证的医疗保健提供者连接起来，从而能够大规模地提供个人化配方的处方药，这些药物比标准非处方药更能精准地满足个体皮肤需求。这种模式有效地解决了皮肤科医疗服务取得的不平等问题，并正在发展成为一种高度扩充性的收入来源。例如，Hims & Hers Health 在 2024 年 11 月发布的「2024 年第三季财务业绩」中报告称，其收入为 4.016 亿美元，同比增长 77%，这主要得益于其个性化皮肤科和健康服务的积极扩张。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球痤疮治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 治疗类型（类视色素、抗生素、荷尔蒙、抗发炎药物、化学换肤、其他）
  • 依剂型（外用、口服、注射）
  • 依类型（处方药、非处方药）
  • 痤疮类型（囊肿型痤疮、术后/伤口痤疮、粉刺型痤疮、发炎性痤疮）
  • 按分销管道（医院、零售店、药局/药局、电子商务）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美痤疮治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲痤疮治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区痤疮治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲痤疮治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲痤疮治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球痤疮治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Johnson & Johnson Services, Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Sanofi SA
• L'Oreal SA
• Procter & Gamble Co.
• Teva Pharmaceutical Industries Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Acne Treatment Market is projected to expand from USD 11.87 Billion in 2025 to USD 16.63 Billion by 2031, registering a CAGR of 5.78%. This market encompasses a wide range of therapeutic agents and procedures, such as systemic antibiotics, topical retinoids, and hormonal therapies, which function by regulating sebum production, inhibiting bacterial growth, and reducing inflammation. Growth is primarily propelled by the rising incidence of acne vulgaris among both adults and adolescents, alongside a global prioritization of physical appearance and skincare. Additionally, the severe psychological toll of the condition, which frequently negatively impacts self-esteem and quality of life, drives individuals to pursue professional dermatological treatment, thereby maintaining demand for effective management solutions.

According to data from the American Academy of Dermatology, in 2025, acne remains the most prevalent skin condition in the United States, impacting up to 50 million Americans annually. This high prevalence highlights the critical need for consistent therapeutic availability. However, the market faces significant hurdles related to the safety profiles of long-term pharmaceutical interventions, specifically the escalating risks of adverse cutaneous reactions and antibiotic resistance. These safety concerns generate hesitation among both patients and prescribers, which potentially restricts the widespread adoption of standard pharmacological regimens and hinders the overall expansion of the sector.

Market Driver

The growing consumer focus on aesthetics and skin health serves as a major driver for market expansion, fundamentally altering the approach to dermatological care. As social media and digital platforms amplify awareness regarding skin appearance, patients are increasingly favoring professional interventions over temporary cosmetic solutions, triggering a surge in demand for clinically validated products that bridge the gap between cosmetics and pharmaceuticals. This trend has fueled rapid growth for major industry players; for instance, L'Oreal's 'Annual Report 2023', released in February 2024, revealed that its Dermatological Beauty Division achieved an impressive like-for-like sales increase of +28.4%, significantly outpacing the general beauty market and highlighting the importance of health-conscious spending in driving the adoption of science-backed acne solutions.

Concurrently, the competitive landscape is being reshaped by the introduction of novel systemic and topical pharmacotherapies that address safety concerns and unmet medical needs linked to traditional antibiotics. Pharmaceutical companies are successfully launching innovative mechanisms, such as androgen receptor inhibitors, that target the hormonal origins of acne while minimizing systemic resistance risks. The rapid uptake of these advanced treatments is reflected in recent data; Cosmo Pharmaceuticals reported in their January 2025 'Preliminary Unaudited 2024 Results' that Winlevi has become the leading branded topical acne treatment in the U.S. with over 1.2 million prescriptions, while Galderma's February 2024 report cited record full-year net sales of 4.082 billion USD, driven by momentum in therapeutic dermatology.

Market Challenge

The safety concerns surrounding long-term pharmaceutical interventions, particularly regarding adverse cutaneous reactions and the growing risk of antibiotic resistance, constitute a major obstacle for the Global Acne Treatment Market. As the medical community becomes more aware of the dangers linked to prolonged antibiotic exposure, prescribers are increasingly hesitant to utilize these traditional high-volume regimens. This clinical caution results in reduced prescription volumes and shorter treatment durations, directly limiting revenue for established systemic agents, while patient anxiety regarding side effects like microbiome disruption further lowers adherence rates and dampens market performance.

Despite these concerns, reliance on these pharmaceuticals remains high, underscoring the magnitude of the industry's challenge. According to the Centers for Disease Control and Prevention, dermatologists prescribed approximately 5.1 million courses of oral antibiotics in 2024, maintaining the highest prescription rate among medical specialists. This heavy prescription volume subjects the dermatology sector to intense pressure from health stewardship programs to significantly curtail usage, consequently restricting market growth as standard-of-care protocols evolve away from these pharmaceutical mainstays to mitigate safety risks.

Market Trends

The rising popularity of hydrocolloid acne patches is fundamentally transforming consumer behavior by validating visible treatment methods and providing a non-invasive alternative to traditional topical applications. Unlike creams that are typically applied discreetly, these adhesive solutions are marketed as lifestyle accessories, which helps reduce the stigma surrounding breakouts while physically shielding the skin barrier from picking and external irritants. This transition toward convenient, single-use formats has created significant commercial momentum for major personal care conglomerates; for example, Church & Dwight's 'Q3 2024 Results' in November 2024 noted that domestic consumer net sales growth was largely driven by the performance of HERO acne products, emphasizing the category's vital role in broader portfolio revenue.

Simultaneously, the expansion of direct-to-consumer teledermatology services is democratizing access to prescription-strength management by overcoming the logistical hurdles of in-office appointments. Digital health platforms utilize asynchronous consultations to link patients with licensed providers, facilitating the scalable delivery of personalized compounded formulations that treat individual skin needs more accurately than standard over-the-counter options. This model effectively bridges the gap in dermatological accessibility and has become a highly scalable revenue source; as evidence, Hims & Hers Health reported in their November 2024 'Third Quarter 2024 Financial Results' a 77% year-over-year revenue surge to $401.6 million, fueled by the aggressive scaling of their personalized dermatology and health offerings.

Key Market Players

• Johnson & Johnson Services, Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Sanofi S.A.
• L'Oreal S.A.
• Procter & Gamble Co.
• Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Acne Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acne Treatment Market, By Therapeutic Class

• Retinoids
• Antibiotics
• Hormonal Drugs
• Anti-Inflammatory Drugs
• Chemical Peels
• Others

Acne Treatment Market, By Formulation

• Topical Medications
• Oral Medications
• Injectables

Acne Treatment Market, By Type

• Prescription Medicines
• Over-The-Counter Medicines

Acne Treatment Market, By Acne Type

• Cystic Acne
• Postsurgical/Wound Acne
• Comedonal Acne
• Inflammatory Acne

Acne Treatment Market, By Distribution Channel

• Hospitals
• Retail Stores
• Pharmacies & Drug Stores
• E-Commerce

Acne Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acne Treatment Market.

Available Customizations:

Global Acne Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acne Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Class (Retinoids, Antibiotics, Hormonal Drugs, Anti-Inflammatory Drugs, Chemical Peels, Others)
  • 5.2.2. By Formulation (Topical Medications, Oral Medications, Injectables)
  • 5.2.3. By Type (Prescription Medicines, Over-The-Counter Medicines)
  • 5.2.4. By Acne Type (Cystic Acne, Postsurgical/Wound Acne, Comedonal Acne, Inflammatory Acne)
  • 5.2.5. By Distribution Channel (Hospitals, Retail Stores, Pharmacies & Drug Stores, E-Commerce)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Acne Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Class
  • 6.2.2. By Formulation
  • 6.2.3. By Type
  • 6.2.4. By Acne Type
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acne Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Class
      • 6.3.1.2.2. By Formulation
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By Acne Type
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Acne Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Class
      • 6.3.2.2.2. By Formulation
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By Acne Type
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Acne Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Class
      • 6.3.3.2.2. By Formulation
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By Acne Type
      • 6.3.3.2.5. By Distribution Channel

7. Europe Acne Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Class
  • 7.2.2. By Formulation
  • 7.2.3. By Type
  • 7.2.4. By Acne Type
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acne Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Class
      • 7.3.1.2.2. By Formulation
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By Acne Type
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Acne Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Class
      • 7.3.2.2.2. By Formulation
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By Acne Type
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Acne Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Class
      • 7.3.3.2.2. By Formulation
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By Acne Type
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Acne Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Class
      • 7.3.4.2.2. By Formulation
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By Acne Type
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Acne Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Class
      • 7.3.5.2.2. By Formulation
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By Acne Type
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Acne Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Class
  • 8.2.2. By Formulation
  • 8.2.3. By Type
  • 8.2.4. By Acne Type
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acne Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Class
      • 8.3.1.2.2. By Formulation
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By Acne Type
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Acne Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Class
      • 8.3.2.2.2. By Formulation
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By Acne Type
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Acne Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Class
      • 8.3.3.2.2. By Formulation
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By Acne Type
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Acne Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Class
      • 8.3.4.2.2. By Formulation
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By Acne Type
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Acne Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Class
      • 8.3.5.2.2. By Formulation
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By Acne Type
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Acne Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Class
  • 9.2.2. By Formulation
  • 9.2.3. By Type
  • 9.2.4. By Acne Type
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acne Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Class
      • 9.3.1.2.2. By Formulation
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By Acne Type
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Acne Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Class
      • 9.3.2.2.2. By Formulation
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By Acne Type
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Acne Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Class
      • 9.3.3.2.2. By Formulation
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By Acne Type
      • 9.3.3.2.5. By Distribution Channel

10. South America Acne Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Class
  • 10.2.2. By Formulation
  • 10.2.3. By Type
  • 10.2.4. By Acne Type
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acne Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Class
      • 10.3.1.2.2. By Formulation
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By Acne Type
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Acne Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Class
      • 10.3.2.2.2. By Formulation
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By Acne Type
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Acne Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Class
      • 10.3.3.2.2. By Formulation
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By Acne Type
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acne Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson & Johnson Services, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc
• 15.3. Pfizer Inc.
• 15.4. Novartis AG
• 15.5. Bayer AG
• 15.6. Eli Lilly and Company
• 15.7. Sanofi S.A.
• 15.8. L'Oreal S.A.
• 15.9. Procter & Gamble Co.
• 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer